Key facts
- This page summarizes George D. Yancopoulos's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2026, 17:54.
George D. Yancopoulos - 31 Dec 2025 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)
- Reporting relationship
- Bd. Co-Chair, President & CSO, Director
- Issuer ticker
- REGN
- Reported as of
- 31 Dec 2025
- Net transaction value
- -$22,058,611
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2026, 17:54:51 UTC
- Prior SEC filing
- 11 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- By: Richard Gluckselig as attorney-in-fact For: George D. Yancopoulos
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
George D. Yancopoulos filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 05 Jan 2026.
Change
- Previous filing in this sequence was filed on 11 Dec 2025.
- Current net transaction value: -$22,058,611.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001226690
Primary reporting owner
YANCOPOULOS GEORGE
- Relationship
- Bd. Co-Chair, President & CSO, Director
- Address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
- Signature
- By: Richard Gluckselig as attorney-in-fact For: George D. Yancopoulos
- Signature date
- 05 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +28,570
- Change %
- +9.2%
- Price
- $0.000000
- Shares after
- 339,030
- Date
- 31 Dec 2025
- Ownership
- Direct
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $22,058,611
- Shares
- -28,570
- Change %
- -8.4%
- Price
- $772.09
- Shares after
- 310,460
- Date
- 31 Dec 2025
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 71,487
- Date
- 31 Dec 2025
- Ownership
- By 2024 GRAT
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200,000
- Date
- 31 Dec 2025
- Ownership
- By 2025 GRAT
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200,000
- Date
- 31 Dec 2025
- Ownership
- By 2025 GRAT II
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,962
- Date
- 31 Dec 2025
- Ownership
- By 401(k) Plan
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 180,000
- Date
- 31 Dec 2025
- Ownership
- By Trust for Chldn.
- Footnotes
- F1
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 101,988
- Date
- 31 Dec 2025
- Ownership
- by 2024 GRAT II
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 56,048
- Date
- 31 Dec 2025
- Ownership
- by Children
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
REGN
transaction
Derivative
2020 Performance Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -28,570
- Change %
- -4.6%
- Price
- $0.000000
- Shares after
- 595,077
- Date
- 31 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,570
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
As investment trustee of trusts for the benefit of the reporting person's children.
Footnote F2
Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.